Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders, completed the previously announced acquisition of 100 per cent of the capital stock of Enobia Pharma Corp. Enobia is a private biopharmaceutical company focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. The company's most significant subsidiary is Montréal-based Enobia Pharma Inc. Under the terms of the agreement, Alexion agreed to pay $610 million in cash upon completion of the transaction and a further amount of up to $470 million in cash upon achievement of various regulatory and sales milestones.
Alexion was represented by its General Counsel, Tom Dubin, and International Counsel, Anne Warner. In Canada, Alexion was represented by Cassels Brock & Blackwell LLP with a team that included Martin Fingerhut (business); Stuart English (life sciences and M&A); Nia Karabatsos (business); Emily Larose (life sciences); Ken Snider, Paul Carenza and Michael Platt (corporate tax); Chris Hersh (competition and life sciences); Imran Ahmed (competition) and Jason Arbuck and Suhuyini Abdulai (financial services). Ropes & Gray LLP acted as external US counsel with a team that included Patrick O'Brien, Michael Mano and Zachary Blume on corporate M&A matters; Anita Varma and Melissa Rones (IP) and Lee Allison (corporate tax).
Enobia was represented by its General Counsel, Eric Tractenberg, and assisted by Canadian external counsel, Norton Rose Canada LLP with a team led by Gino Martel and including Derek Chiasson and Ted Citrome (tax); Meghan Stewart (corporate/M&A); Thierry Dorval (competition) and Pascal Rodier (banking) and by US external counsel, Wilmer Cutler Pickering Hale and Dorr LLP with a team that included Hal Leibowitz, Jeffrey Hermanson, Belinda Juran, Amy Null, Roger Ritt, Kimberly Wade, Brett Budzinski and Meghan Walsh.